Cargando…

Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma

Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and new treatment strategies are needed. Ovarian cancer tumors are known to host an immunosuppressive microenvironment. This suppression may be reversible via activation of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Brueseke, Taylor J, Tewari, Krishnansu S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666910/
https://www.ncbi.nlm.nih.gov/pubmed/23723721
http://dx.doi.org/10.2147/CPAA.S40401
_version_ 1782271406781759488
author Brueseke, Taylor J
Tewari, Krishnansu S
author_facet Brueseke, Taylor J
Tewari, Krishnansu S
author_sort Brueseke, Taylor J
collection PubMed
description Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and new treatment strategies are needed. Ovarian cancer tumors are known to host an immunosuppressive microenvironment. This suppression may be reversible via activation of the innate immune response. Toll-like receptor 8 activates innate immunity while simultaneously inhibiting the effects of regulatory T cells within the ovarian cancer tumors. VTX-2337 is a novel small molecule ligand of Toll-like receptor 8 and is currently the subject of a Phase II randomized, double-blind, placebo-controlled trial Gynecologic Oncology Group (GOG)-3003 for patients with recurrent platinum-resistant ovarian cancer. We look forward to the results of this trial as support for the paradigm of process therapy in the treatment of ovarian cancer.
format Online
Article
Text
id pubmed-3666910
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36669102013-05-30 Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma Brueseke, Taylor J Tewari, Krishnansu S Clin Pharmacol Review Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and new treatment strategies are needed. Ovarian cancer tumors are known to host an immunosuppressive microenvironment. This suppression may be reversible via activation of the innate immune response. Toll-like receptor 8 activates innate immunity while simultaneously inhibiting the effects of regulatory T cells within the ovarian cancer tumors. VTX-2337 is a novel small molecule ligand of Toll-like receptor 8 and is currently the subject of a Phase II randomized, double-blind, placebo-controlled trial Gynecologic Oncology Group (GOG)-3003 for patients with recurrent platinum-resistant ovarian cancer. We look forward to the results of this trial as support for the paradigm of process therapy in the treatment of ovarian cancer. Dove Medical Press 2013-05-23 /pmc/articles/PMC3666910/ /pubmed/23723721 http://dx.doi.org/10.2147/CPAA.S40401 Text en © 2013 Brueseke and Tewari, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Brueseke, Taylor J
Tewari, Krishnansu S
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title_full Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title_fullStr Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title_full_unstemmed Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title_short Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title_sort toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666910/
https://www.ncbi.nlm.nih.gov/pubmed/23723721
http://dx.doi.org/10.2147/CPAA.S40401
work_keys_str_mv AT brueseketaylorj tolllikereceptor8augmentationofinnateimmunityinplatinumresistantovariancarcinoma
AT tewarikrishnansus tolllikereceptor8augmentationofinnateimmunityinplatinumresistantovariancarcinoma